ArticleClinical rheumatology2026
Elevated proportion of BST2 + CD4 + T cells: a potential biomarker for diagnosis and disease activity in Sjögren's disease.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectiveWe constructed a gene coexpression network to uncover central key genes related to Sjögren's disease (SjD), and investigated the clinical significance of bone marrow stromal antigen 2 (BST2) in SjD.
methodsTwo microarray datasets (GSE84844 and GSE66795) were analyzed to construct a gene coexpression network and identify hub genes, using the GSE51092 dataset for validation. The expression of the hub gene BST2 in peripheral blood mononuclear cells (PBMCs) was quantified using reverse transcription quantitative polymerase chain reaction (RT-qPCR), and BST2 expression on T cells subsets was measured using flow cytometry in 35 SjD and 20 healthy controls (HC). Furthermore, we analyzed the correlations between the proportion of BST2 + CD4 + T cells and various clinical and laboratory features.
resultsSixteen hub genes (BST2, IFI27, IFI6, PARP12, HERC6, PLSCR1, LY6E, EIF2AK2, GBP1, IFI44L, RTP4, IFIT2, MX1, OASL, GBP5, and XAF1) were identified through WGCNA. BST2 mRNA expression showed significantly elevated in SjD than HC (p < 0.05). Compared to HC, the proportions of BST2 + cells were markedly higher among the CD3 + , CD4 + , and CD8 + T cell subsets in SjD (p < 0.05). The proportion of BST2 + CD4 + T cells was positively associated with serum IgG and ESR and negatively associated with serum C3 (all p < 0.05). BST2 + CD4 + T cells proportions were more greater in patients with ≥ 2 involved organ systems, fatigue, anemia, interstitial lung disease, high IgG levels, or rheumatoid factor positivity than in those without these manifestations (p < 0.05). Receiver operating characteristic (ROC) curve analysis revealed that the proportion of BST2 + CD4 + T cells was good for the diagnosis and disease activity of SjD.
conclusionsThese findings suggest that BST2 may serve as a potential biomarker for identifying and evaluating disease activity of SjD, but further investigattion of this biomarker in SjD is needed. Key Points • Compared with that in HC, the mRNA expression of BST2 in SjD significantly increased. • The proportion of BST2+CD4+ T cells was elevated in SjD, especially among those with active disease and multi-system involvement. • The proportion of BST2+CD4+ T cells was good for diagnosing and evaluating the disease activity of SjD.
Indexed as
Identifiers
41954819What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.